Toby M. Maher
← Back to Imperial College London
Imperial College London
Toby M. Maher works in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Pulmonary Hypertension Research and Treatments, Systemic Sclerosis and Related Diseases, Occupational and environmental lung diseases. Recorded institutional associations include University of Southern California, University of California, Los Angeles, Royal Brompton Hospital.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
2022 · 2,827 citationsNintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 · 1,642 citationsAcute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
2016 · 1,437 citationsInterstitial Lung Disease in Systemic Sclerosis
2008 · 1,230 citationsGenome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
2013 · 805 citationsIdiopathic pulmonary fibrosis: Disease mechanisms and drug development
2020 · 636 citationsPirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
2019 · 628 citationsGlobal incidence and prevalence of idiopathic pulmonary fibrosis
2021 · 612 citationsNintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
2020 · 569 citationsThe Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
2014 · 566 citationsInterstitial lung diseases
2022 · 539 citationsPulmonary fibrosis secondary to COVID-19: a call to arms?
2020 · 481 citationsPleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes
2012 · 392 citationsInterstitial Lung Disease
2024 · 388 citationsPD-1 up-regulation on CD4 + T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
2018 · 363 citationsShort‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis
2017 · 354 citationsIdiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
2007 · 341 citationsGenome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis
2019 · 327 citationsIncreased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
2009 · 319 citationsPulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?
2016 · 315 citationsLongitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
2015 · 312 citationsInterleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
2019 · 310 citationsThe identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
2020 · 310 citationsGenetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study
2017 · 296 citationsPotential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
2019 · 296 citations
